← back to search

Yoshiko Atsuta

Aichi Medical University · JP
Area of research
Hematology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia Research, Acute Lymphoblastic Leukemia research, and Chronic Myeloid Leukemia Treatments.
h-index
61
citations
16,842
works
948
NIH funding
primary concept
Medicine
email

Recent publications

DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study.
2026cited by 4position: contributordoi
Impact of methotrexate-dosing regimens for GVHD prophylaxis on clinical outcomes of HLA-matched allogeneic HSCT.
2026cited by 1position: contributordoi
Can Cord Blood Unit Selection Improve Outcomes After Single-Unit Unrelated Cord Blood Transplantation for Non-Remission Acute Myeloid Leukemia?
Transplantation and Cellular Therapy 2026cited by 1position: contributordoi
Maintenance Treatment With Gilteritinib Suppresses Post-transplant Relapse in Relapse/Refractory FLT3-Mutated Acute Myeloid Leukemia
Transplantation and Cellular Therapy 2026cited by 1position: contributordoi
The Limited Impact of Pre-existing Rheumatologic Diseases on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Propensity–Score Matched Analysis
Transplantation and Cellular Therapy 2026cited by 1position: contributordoi
Letermovir prophylaxis and risk of bacterial or fungal infection after allogeneic hematopoietic cell transplantation
Journal of Infection and Chemotherapy 2026cited by 1position: contributordoi
Optimizing Patient Selection for Reduced Nonrelapse Mortality After Reduced-Intensity Conditioning: A CIBMTR Analysis.
2026cited by 0position: contributordoi
Outcomes of hematopoietic stem cell transplantation for patients with monomorphic epitheliotropic intestinal T-cell lymphoma: retrospective study from the Adult Lymphoma Working Group of the Japan Society for Transplantation and Cellular Therapy.
2026cited by 0position: contributordoi
Drivers of Temporal Improvement in CAR T-Cell Therapy for Large B-Cell Lymphoma: A Japanese Nationwide Registry Analysis.
2026cited by 0position: contributordoi
The role of HLA transcription in unrelated hematopoietic cell transplantation.
2026cited by 0position: contributordoi
Disease status at CAR T-cell infusion in relapsed or refractory large B-cell lymphoma: prognostic significance for real-world outcomes, irrespective of bridging therapy.
2026cited by 0position: contributordoi
GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study.
2026cited by 0position: contributordoi
Impact of antiviral therapies on survival in patients with HHV-6B encephalitis after cord blood transplantation: a real-world study.
2026cited by 0position: contributordoi
HLA-matched versus haploidentical donor transplantation with post-transplant cyclophosphamide: a study on behalf of the donor/source working group of the Japanese society for transplantation and cellular therapy.
2026cited by 0position: contributordoi
Long-read KIR genotyping reveals donor KIR/HLA polymorphisms linked to posttransplant relapse in T-cell malignancies.
2026cited by 0position: contributordoi
Comparison of single-unit umbilical cord blood transplantation and haploidentical transplantation using posttransplant cyclophosphamide during first complete remission of acute myeloid leukemia.
2026cited by 0position: contributordoi
Vaccine-Induced Anti-HBs Response Is Associated with Protection Against Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Cell Transplantation: A Randomized Trial
Transplantation and Cellular Therapy 2026cited by 0position: contributordoi
Second Allogeneic Hematopoietic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma: A Nationwide Registry Analysis
Transplantation and Cellular Therapy 2026cited by 0position: contributordoi
Older patients with LBCL show comparable outcomes to younger patients and product-specific profiles in CAR-T therapy
Blood Immunology & Cellular Therapy 2026cited by 0position: contributordoi
Subsequent Neoplasms After Umbilical Cord Blood Transplantation in the Japanese and European Populations
Transplantation and Cellular Therapy 2026cited by 0position: contributordoi
Comparison of stem cell mobilization methods in multiple myeloma
Cytotherapy 2026cited by 0position: contributordoi
Real-world outcomes of tisagenlecleucel treatment in patients with relapsed or refractory large B-cell lymphomas: a nationwide registry
Cytotherapy 2026cited by 0position: contributordoi
Real-World Data and Real-World Evidence in Regulatory Decision Making: Report Summary From the Council for International Organizations of Medical Sciences (CIOMS) Working Group XIII.
2025cited by 11position: contributordoi
Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post-transplantation cyclophosphamide for adult T-cell leukaemia/lymphoma.
2025cited by 7position: contributordoi
An ASTCT, CIBMTR, EBMT, and APBMT Consensus Statement Defining Response Criteria for Hematopoietic Cell Transplantation Associated Thrombotic Microangiopathy (TA-TMA) Directed Therapy
Transplantation and Cellular Therapy 2025cited by 6position: contributordoi
Impact of haplo-donor age on transplant outcomes: a comparative analysis of haploidentical vs cord blood transplantation.
2025cited by 4position: contributordoi
Setting up a Chimeric Antigen Receptor T Cell Therapy Program: A Framework for Delivery from the Worldwide Network for Blood & Marrow Transplantation
Transplantation and Cellular Therapy 2025cited by 4position: contributordoi
Comparison of Nonrelapse Mortality After Haploidentical Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide Versus Single Umbilical Cord Blood Transplantation in Hematologic Disease
Transplantation and Cellular Therapy 2025cited by 4position: contributordoi
Setting up a Chimeric Antigen Receptor T Cell Therapy Program: A Framework for Delivery from the Worldwide Network for Blood & Marrow Transplantation
Transplantation and Cellular Therapy 2025cited by 3position: middledoi
Superior Survival After Unrelated Allogeneic Stem Cell Transplantation With Low-Dose ATG Compared to Low-Dose TBI in Myeloablative Fludarabine/Busulfan-Based Regimen for MDS on Behalf of the Adult MDS Working Group of the JSTCT
Transplantation and Cellular Therapy 2025cited by 3position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 201 papers (2019–2026)Naoyuki Uchida · Toranomon Hospital83 papers (2021–2026)Junya Kanda · Japan Advanced Institute of Science and Technology80 papers (2019–2026) · 79 papers (2019–2026) · 60 papers (2021–2026)Yoshinobu Kanda · Japanese Society for Dialysis Therapy60 papers (2021–2026)Tatsuo Ichinohe · Hiroshima University58 papers (2021–2026)Noriko Doki · Tokyo Metropolitan Komagome Hospital54 papers (2021–2026)Shuichi Ota · Sapporo Hokuyu Hospital42 papers (2021–2026) · 39 papers (2021–2026)Masamitsu Yanada · Nagoya City University38 papers (2021–2026)Yuta Katayama · Japanese Red Cross Hiroshima College of Nursing35 papers (2021–2026)Hirohisa Nakamae · Osaka City University32 papers (2021–2026)Hideki Nakashone · Jichi Medical University30 papers (2021–2026)Shinichi Kako · Jichi Medical University27 papers (2020–2026)Ken-ichi Matsuoka · Okayama University26 papers (2021–2025) · 26 papers (2021–2026)Tadakazu Kondo · Kobe University Hospital26 papers (2021–2026)Masatsugu Tanaka · Kanagawa Cancer Center24 papers (2022–2026)Yoshimitsu Shimomura · Springer Nature24 papers (2019–2026)